TEM:NASDAQTempus AI, Inc. Analysis

Tempus AI has delivered an impressive **83% year‑over‑year revenue surge** to $1.27 B, supported by a solid 62% gross margin, but its operating margin remains deeply negative at –16.7% and cash flow is still in the red, with $112 M of negative free cash flow and a debt‑to‑equity ratio of 270%. The balance sheet is strained – $1.33 B of debt versus $0.75 B of cash – and the company trades at a **price‑to‑book of 20×** and a **price‑to‑sales of 7.8×**, far above industry averages, while the forward P/E sits at –611, underscoring an overvalued pricing profile. Nonetheless, strategic partnerships announced this quarter – an expanded multi‑year collaboration with Gilead Sciences and 31 abstracts accepted for presentation at AACR 2026 – reinforce its growth narrative and could accelerate adoption of its AI‑driven diagnostics platform.
Technical signals are mixed: the 20‑day SMA (51.7) sits above the 50‑day SMA (50.7) but both lag the 200‑day SMA (67.1), the MACD histogram is positive (0.33) indicating short‑term bullish momentum, and RSI is neutral at 57. The stock trades at $55.3, comfortably above the $42.4 support level yet below the $58.0 resistance, offering a **30.9% upside/downside** asymmetry. High volatility (77% 30‑day) and a beta of 2.68 amplify market risk, while decreasing volume hints at waning short‑term liquidity. Investor sentiment is extreme greed (Fear & Greed Index 89), suggesting speculative enthusiasm that may not be fully justified by fundamentals.